Victoria's Secret & Co DEFA14A, filed May 12, 2026
Victoria's Secret & Co. (VSXY)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material under § 240.14a-12 |
Victoria’s Secret & Co.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Explanatory Note
On May 11, 2026, Victoria’s Secret & Co. (“VS&Co” or the “Company”) filed with the Securities and Exchange Commission (“SEC”) and began the process of printing a supplement (the “Proxy Supplement”) to its Proxy Statement (the “Proxy Statement”) for the Company’s 2026 Annual Meeting of Stockholders (including any adjournment or postponement thereof, the “Annual Meeting”).
The Company is filing these definitive additional materials solely to correct certain inadvertent errors contained within the table filed with the SEC in the section entitled “Information Regarding Transactions in the Company’s Securities by Participants” included in the Appendix to the Proxy Supplement. The correct table, which is included in the printed version of the Proxy Supplement that will be distributed to certain stockholders of the Company, is set forth below:
Company Securities Purchased or Sold
(May 1, 2024 through May 11, 2026)
| Name | Transaction Date |
Number of Securities |
Transaction Notes |
|||||||||
| Irene Chang Britt |
06/18/2025 | 7,440 | ||||||||||
| 06/13/2024 | 7,796 | |||||||||||
| Sarah Davis |
06/18/2025 | 7,304 | ||||||||||
| 06/13/2024 | 7,654 | |||||||||||
| Donna James |
04/02/2026 | 2,175 | ||||||||||
| 06/18/2025 | 12,739 | |||||||||||
| 09/12/2024 | 1,000 | |||||||||||
| 06/13/2024 | 12,210 | |||||||||||
| Jacqueline Hernández |
06/18/2025 | 7,304 | ||||||||||
| 06/13/2024 | 7,654 | |||||||||||
| Rod Little |
06/18/2025 | 6,761 | ||||||||||
| 06/13/2024 | 7,084 | |||||||||||
| David McCreight |
06/18/2025 | 7,304 | ||||||||||
| 04/03/2025 | 3,246 | |||||||||||
| Lauren Peters |
06/18/2025 | 7,440 | ||||||||||
| 06/13/2024 | 7,796 | |||||||||||
| Anne Sheehan |
04/02/2026 | 633 | ||||||||||
| 06/18/2025 | 7,304 | |||||||||||
| 06/13/2024 | 7,654 | |||||||||||
| Hillary Super |
03/19/2026 | 80,662 | ||||||||||
| 03/19/2026 | (23,294 | ) | ||||||||||
| 10/07/2025 | (39,045 | ) | ||||||||||
| 03/19/2025 | 142,066 | |||||||||||
| 10/07/2024 | 237,800 | |||||||||||
| Scott Sekella |
03/19/2026 | 30,765 | ||||||||||
| 02/03/2026 | (2,061 | ) | ||||||||||
| 09/02/2025 | 11,161 | |||||||||||
| 02/03/2025 | 21,484 | |||||||||||
| Melinda McAfee |
03/19/2026 | 16,546 | ||||||||||
| 03/19/2026 | (13,445 | ) | ||||||||||
| 03/16/2026 | (11,679 | ) | ||||||||||
| 02/19/2026 | 20,256 | 1 | ||||||||||
| 10/31/2025 | (2,221 | ) | ||||||||||
| 03/19/2025 | 53,621 | |||||||||||
| 03/19/2025 | (7,764 | ) | ||||||||||
| 03/16/2025 | (7,351 | ) | ||||||||||
| 02/20/2025 | 9,400 | |||||||||||
| 10/31/2024 | (1,020 | ) | ||||||||||
| 08/18/2024 | (214 | ) | ||||||||||
| 05/19/2024 | (1,328 | ) | ||||||||||
| Mariam Naficy |
06/18/2025 | 6,625 | ||||||||||
| 06/13/2024 | 6,942 |
Transaction Descriptions
| 1 | The reported acquired securities represent shares issued in settlement of performance share units granted on March 16, 2023 for which the Human Capital and Compensation Committee has certified achievement of performance. |
Except as described in this Explanatory Note, the information contained in the Proxy Statement, as supplemented and amended by the Proxy Supplement, remains unchanged.